Take off the wrapper
9 October 2020

An Oaktree-backed blank-check company is paying a relative bargain for fast-growing online drug seller Hims. But the target is expanding from easily sold drugs for hair loss and erectile dysfunction into harder categories such as diabetes. That’ll limit its efficacy.